Literature DB >> 6111027

Effects of dopaminergic and cholinergic drugs. naloxone and l-prolyl-leucyl-glycinamide on LSD-induced catalepsy.

S Chiu, R K Mishra.   

Abstract

In an attempt to elucidate the mechanism of d-lysergic acid diethylamide (LSD) induced catalepsy, the effects of cholinergic and dopaminergic agents, naloxone and L-propyl-leucyl-glycinamide (PLG) were studied in rats. The dose-dependent (50--500 micrograms kg-1 s.c.) and time-related cataleptic response elicited by LSD was preceded by a phase of hyperexcitability. The non-hallucinogenic analogue, 2-bromo-LSD (BOL), was without effect. Both apomorphine, the dopamine agonist, and L-DOPA antagonized LSD-induced catalepsy whereas the dopamine depleting agent alpha-methyl-p-tyrosine (alpha-MPT) slightly prolonged the cataleptic effect. Cholinergic muscarinic receptor stimulation with pilocarpine antagonized LSD-induced catalepsy. The muscarinic antagonists, atropine and scopolamine, intensified the hyperexcitable phase and potentiated the cataleptic effects of LSD. Nicotine slightly potentiated LSD action but mecamylamine antagonized it. While pre-treatment with naloxone, the narcotic antagonist and PLG prolonged the cataleptic response, post-treatment with naloxone effectively attenuated LSD-induced catalepsy. The behavioural data are interpreted to suggest that LSD-induced catalepsy may be mediated through diminished dopaminergic and cholinergic neuronal activity and under enkephalinergic modulation. The neuroanatomical foci and exact mechanism of action remain to be delineated.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6111027     DOI: 10.1007/bf00505804

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  31 in total

1.  The effects of repeated D-lysergic acid diethylamide injections on catecholamine levels and tyrosine hydroxylase activity in rat brain regions.

Authors:  D A Peters; S Tang
Journal:  J Neurochem       Date:  1977-01       Impact factor: 5.372

2.  Effects of lisuride and LSD on cerebral monoamine systems and hallucinosis.

Authors:  L Pieri; H H Keller; W Burkard; M Da Prada
Journal:  Nature       Date:  1978-03-16       Impact factor: 49.962

3.  Electrophysiological evidence for a dopaminergic action of LSD: depression of unit activity in the substantia nigra of the rat.

Authors:  G R Christoph; D M Kuhn; B L Jacobs
Journal:  Life Sci       Date:  1977-12-01       Impact factor: 5.037

4.  Antagonism of morphine-induced catalepsy by L-prolyl-L-leucyl-glycinamide.

Authors:  S Chiu; R K Mishra
Journal:  Eur J Pharmacol       Date:  1979-01-01       Impact factor: 4.432

5.  Comparative effects of hallucinogenic drugs on rotational behavior in rats with unilateral 6-hydroxydopamine lesions.

Authors:  M E Trulson; A D Stark; B L Jacobs
Journal:  Eur J Pharmacol       Date:  1977-07-15       Impact factor: 4.432

6.  Catalepsy induced by morphine or haloperidol: effects of apomorphine and anticholinergic drugs.

Authors:  C Erzin-Waters; P Muller; P Seeman
Journal:  Can J Physiol Pharmacol       Date:  1976-08       Impact factor: 2.273

7.  Parkinsonism by haloperidol and piribedil.

Authors:  G U Corsini; M Del Zompo; A Spissu; A Mangoni; G L Gessa
Journal:  Psychopharmacology (Berl)       Date:  1978-10-31       Impact factor: 4.530

8.  Effect of cholingeric drugs on methadone-induced catalepsy and stereotypies in rats treated chronically with methadone.

Authors:  L Ahtee
Journal:  Eur J Pharmacol       Date:  1976-10       Impact factor: 4.432

9.  Effect of muscarinic cholinergic drugs on morphine-induced catalepsy, antinociception and changes in brain dopamine metabolism.

Authors:  S Kaakkola; L Ahtee
Journal:  Psychopharmacology (Berl)       Date:  1977-03-23       Impact factor: 4.530

10.  Interaction between narcotic antagonist (naloxone) and lysergic acid diethylamide (LSD) in the rat.

Authors:  A P Fertziger; R Fischer
Journal:  Psychopharmacology (Berl)       Date:  1977-11-15       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.